Haemonetics公司推出心脏旁路手术血液救援系统

一种血液救援系统使得外科医生能够在心血管手术术中与术后恢复患者的失血，从而将血液回输给患者。该系统已经获得了美国食品药品管理局的许可。

该系统叫做CardioPAT，设计用于保证患者能够输到最安全的血液，也就是患者自己的血液。设备功能更加完善，使得系统十分适合在泵功能停止或者仍然跳动的心脏进行自身输血。系统不仅能够在手术室而且还能够在重症监护室抢救患者失血。CardioPAT是Haemonetics公司的产品，该公司开发了细胞拯救平台并领导着外科血液救援市场。

Haemonetics估计每年大约有20％的冠状动脉旁路手术使用泵功能停止技术。该公司已经在美国三家单位开始了消费者能够接受的临床试验。公司指出：在前期欧洲的临床试验中，该系统表现良好。

英国James Cook大学医院心胸外科临床主任Andrew Owens主持了第一个临床试验，他评论说：“这是一项令人兴奋的技术，将会为心脏病患者带来巨大的利益。系统使得患者能够回输自己的血液，而且帮助血库节约血液用于其它患者。”

Blood Salvage System for Bypass Surgery
 
A blood salvage system allows surgeons to recover blood lost by a patient during and after cardiovascular surgery and makes the blood available for transfusion back to the patient. The system has been cleared by the U.S. Food and Drug Administration (FDA).

Called CardioPAT, the system is designed to ensure that patients are transfused with the safest blood possible, which is their own. A device provides better functionality that makes the system ideally suited for providing autotransfusion during off-pump, or beating-heart, surgery. The system can salvage blood lost both in the operating room and during recovery in the intensive care unit. CardioPAT is the product of Haemonetics Corp. (Braintree, MA, USA), whose Cell Saver platform created and leads the surgical blood salvage market.

Haemonetics estimated that about 20% of annual coronary artery bypass graft surgeries use the off-pump surgical technique. The company is beginning customer-acceptance trials at three U.S. sites. In prior trials in Europe, the system performed very well, the company noted.

“This is a very exciting technique that will have compelling benefits for heart patients,” remarked Dr. Andrew Owens, clinical director of cardiothoracic surgery at the James Cook University Hospital (Middlesbrough, UK), who led the first trials. “The system gives patients the advantage of getting their own blood back, but also helps ensure that banked blood is available for other patients.”